| 1. |
O’Neill BD, Brown G, Heald RJ, et al. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol, 2007, 8(7): 625-633.
|
| 2. |
Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol, 2010, 11(9): 835-844.
|
| 3. |
Yeo SG, Kim DY, Kim TH, et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG09-01). Ann Surg, 2010, 252(6): 998-1004.
|
| 4. |
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004, 351(17): 1731-1740.
|
| 5. |
Zorcolo L, Rosman AS, Restivo A, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol, 2012, 19(9): 2822-2832.
|
| 6. |
Jia H, Shen X, Guan Y, et al. Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer. Radiother Oncol, 2018, 128(3): 548-556.
|
| 7. |
Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years. J Clin Oncol, 2012, 30(16): 1926-1933.
|
| 8. |
Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg, 2012, 99(7): 918-928.
|
| 9. |
Duldulao MP, Lee W, Streja L, et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis Colon Rectum, 2013, 56(2): 142-149.
|
| 10. |
Tranchart H, Lefèvre JH, Svrcek M, et al. What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer? Ann Surg Oncol, 2013, 20(5): 1551-1559.
|
| 11. |
Guedj N, Maggiori L, Poté N, et al. Distal intramural and tumor spread in the mesorectum after neoadjuvant radiochemotherapy in rectal cancer: about 124 consecutive patients. Hum Pathol, 2016, 52: 164-172.
|
| 12. |
Lin JZ, Peng JH, Qdaisat A, et al. Preoperative chemoradiotherapy creates an opportunity to perform sphincter preserving resection for low-lying locally advanced rectal cancer based on an oncologic outcome study. Oncotarget, 2016, 7(35): 57317-57326.
|
| 13. |
Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol, 1999, 17(8): 2396.
|
| 14. |
Gerard JP, Chapet O, Nemoz C, et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the Lyon R96-02 randomized trial. J Clin Oncol, 2004, 22(12): 2404-2409.
|
| 15. |
Endreseth BH, Myrvold HE, Romundstad P, et al. Transanal excision vs. major surgery for T1 rectal cancer. Dis Colon Rectum, 2005, 48(7): 1380-1388.
|
| 16. |
Bentrem DJ, Okabe S, Wong WD, et al. T1 adenocarcinoma of the rectum: transanal excision or radical surgery? Ann Surg, 2005, 242(4): 472-477.
|
| 17. |
Jung SM, Yu CS, Park IJ, et al. Oncologic safety of local excision compared with total mesorectal excision for ypT0-T1 rectal cancer: a propensity score analysis. Medicine (Baltimore), 2016, 95(20): e3718.
|
| 18. |
Shin YS, Yu CS, Park JH, et al. Total mesorectal excision versus local excision after favorable response to preoperative chemoradiotherapy in " early” clinical T3 rectal cancer: a propensity score analysis. Int J Radiat Oncol Biol Phys, 2017, 99(1): 136-144.
|
| 19. |
Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg, 2009, 250(4): 582-589.
|
| 20. |
Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol, 2016, 34(31): 3773-3780.
|
| 21. |
Du D, Su Z, Wang D, et al. Optimal interval to surgery after neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer, 2018, 17(1): 13-24.
|
| 22. |
Wolthuis AM, Penninckx F, Haustermans K, et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol, 2012, 19(9): 2833-2841.
|
| 23. |
Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg, 2006, 93(10): 1215-1223.
|
| 24. |
Wu H, Fang C, Huang L, et al. Short-course radiotherapy with immediate or delayed surgery in rectal cancer: A meta-analysis. Int J Surg, 2018, 56: 195-202.
|
| 25. |
Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol, 2012, 30(31): 3827-3833.
|
| 26. |
Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg, 2004, 240(4): 711-717.
|
| 27. |
Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum, 2013, 56(10): 1109-1117.
|
| 28. |
Habr-Gama A, Perez RO, Wynn G, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum, 2010, 53(12): 1692-1698.
|
| 29. |
Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol, 2011, 29(35): 4633-4640.
|
| 30. |
Li J, Li L, Yang L, et al. Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Oncotarget, 2016, 7(28): 44857-44870.
|
1/5
WeChat